Probably futile and a fool’s errand but I thought I’d compare...

Probably futile and a fool’s errand but I thought I’d compare PYC’s possible future to CSL now.

CSL has 483 million SOI and a MCAP of $146 billion. Last year it made NPAT of US$2.75 billion on revenue of US$14.8 billion (=18.6% of sales).

I’m going to assume PYC licenses out the RP11 treatment and that gives the SP a kick up and also funds the development of the PKD in-house.
I’m assuming the 330,000 PKD patients in the US are all treated and the cost of the treatment is AD$75,000 p.a. Revenue is thus about $24 billion. Assuming a NPAT of 20% (similar to CSL but we should be better) gives NPAT of $4.8 billion. Let’s say $4.7 billion and we have 4.7 billion SOI, so AD$1/share. If that is equivalent to 5% ROI, then each PYC share is valued at $20.
Note that I’m not including any possible value from other assets in the pipeline. And I’m using a very low treatment cost. And not counting any patients outside the USA.

Please point out any glaring errors I have made.
All I can say (if the above crude maths is correct) is “GIDDYUP!”